Business Wire

Valeo Foods Group Accelerates Growth in Eastern Europe With Acquisition of Prestige-96, a Leading Bulgarian Sweet Baked Goods Player

19.3.2026 08:00:00 CET | Business Wire | Press release

Share

Valeo Foods Group, one of Europe’s leading producers of sweets, treats and snacks, today announced that it has reached an agreement to acquire 100% of Prestige-96 AD (“Prestige”), a market-leading Bulgarian manufacturer of sweet baked goods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319225232/en/

Prestige-96 sandwich biscuits.

Founded in 1996, Prestige is one of Bulgaria’s most established and trusted producers of biscuits, wafers and sweet snack products. Its portfolio features some of the country’s most recognisable local brands including - Naya (Ная), Hyper (Хайпър), Mirage (Мираж) and Roden Kray (Роден Край). Prestige employs approximately 450 people across its operations.

The acquisition marks a significant milestone in Valeo Foods Group’s long-term growth strategy, focused on acquiring market-leading, iconic local brands as part of its continued European expansion. As Valeo Foods Group’s eighth acquisition since 2022, Prestige reinforces the company’s ambition to strengthen its position as Europe’s leading sweet treats champion.

Integrating Prestige into the Group is expected to unlock significant strategic value. The combined business will accelerate growth in Bulgaria by enhancing cross-selling opportunities and capitalising on Prestige’s strong retailer relationships. The acquisition also creates new pathways to expand into adjacent snacking categories and broadens Valeo Food Group’s international footprint by leveraging the export strengths of both organisations to grow in existing and new markets.

In addition, Prestige brings a modern, well‑invested production and warehousing facility, enhancing the Group’s capacity, operational flexibility and overall efficiency.

Prestige’s experienced local management team shares Valeo Foods’ commitment to quality, operational excellence and long‑term business resilience. Their expertise and strong cultural alignment will play a key role in advancing the Group’s ambition to become Europe’s undisputed sweet treats champion.

Ronald Kers, CEO of Valeo Foods Group, commented: "Prestige is an exceptional business with outstanding brands, a strong market position, and a highly capable team. By combining Prestige’s category expertise with the scale of the Valeo Foods network, we see significant opportunities to accelerate growth, expand into new markets, and bring even more loved products to consumers across Europe. This acquisition is a clear investment in long‑term, sustainable growth, adding capabilities that naturally enhance our core business. We look forward to welcoming the Prestige team as we grow together.”

Darina Stoyanova, CEO of Prestige 96, said:
“Prestige has grown into one of Bulgaria’s leading sweet snacking companies thanks to the dedication of our people and the trust of our consumers. Joining Valeo Foods gives us an even stronger platform to build on that success. By combining Prestige’s much‑loved brands with Valeo Foods’ international scale and capabilities, we see tremendous potential to grow our business, reach new markets and continue delivering the products consumers love.”

Completion of the transaction is subject to customary regulatory approvals in Bulgaria. Terms of the deal will not be disclosed.

About Valeo Foods Group

Valeo Foods Group is a leading international food business, specialising in producing high-quality sweets, snacks, and treats. Our diverse portfolio includes over 80 brands including market-leaders such as Balconi cakes, Barratt sweets, Pedro confectionery, Horalky, Lina and Mila wafers, Rowse Honey, Bernard maple syrup, and Kettle Chips. With revenues close to €2 billion, the Group employs over 5,500 people across 30 manufacturing facilities and offices in the UK, Italy, Germany, the Netherlands, Ireland, the Central and Eastern Europe and North America. Valeo Foods Group is owned by leading global investment firm Bain Capital.

About Prestige 96

Prestige is one of Bulgaria’s most recognisable FMCG companies and a market leader in its core categories - biscuits, wafers, and mini cakes in Bulgaria. Renowned for its commitment to quality and superior taste, Prestige has successfully expanded its footprint, with high-quality products now available in over 30 countries worldwide. An owner of trusted brands with exceptional loyalty like Naya (Ная), Mirage (Мираж), Trayana (Траяна), Roden Kray (Роден Край), Hyper (Хипер), Spoko (Споко), Prestige Wellness, the company has built a well-diversified sweet baked goods portfolio that continues to drive growth and innovation. Prestige employs approximately 450 people across its operations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260319225232/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye